Tomasello Shawn 4

What Happened Shawn Tomasello, a director of Cabaletta Bio, was granted a 22,000-share derivative award (reported as $0.00 per share) on 2026-06-09. The Form 4 lists this as a grant/award (transaction type A) — not a cash purchase or sale — so no immediate cash changed hands. The filing reports the award as a derivative instrument (e.g., stock option or similar).

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-10 (appears timely).
• Award: 22,000 shares reported at $0.00 (derivative/award).
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: The option/award vests in full upon the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of stockholders.
• No indication of a 10b5-1 plan, cashless exercise, tax-withholding sale, or late filing in this submission.

Context This is a standard director compensation award rather than an open-market purchase or sale. As a derivative grant with a future vesting date, it does not provide immediate liquidity and should be treated as part of routine compensation unless additional related transactions or disclosures follow. Purchases by insiders can be more directly interpreted as buying signals; grants/awards mainly reflect compensation practices.